Pfizer's BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer

Core Insights - Pfizer Inc. announced updated follow-up results from the Phase 2 PHAROS trial for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in treating adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation [1] Group 1 - In treatment-naïve patients, the median overall survival (OS) was reported at 47.6 months with a 95% confidence interval of 31.3 months, not estimable after a median follow-up of 52.3 months [1]